NCT01038778 2026-04-13
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
78 trialsNCT02830724 2026-04-06
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05267626 2026-03-31
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT03745326 2026-03-19
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04347616 2026-03-16
NK4AML
Radboud University Medical Center
Phase 1/2 Terminated
NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05639972 2026-02-27
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Rutgers, The State University of New Jersey
Phase 1/2 Recruiting
NCT04426669 2026-02-23
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
Phase 1/2 Completed
NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
NCT07389239 2026-02-20
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
University of Chicago
Phase 1/2 Not yet recruiting
NCT03190941 2025-12-02
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05194735 2025-11-10
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
Phase 1/2 Terminated
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT07063875 2025-07-14
SILVER
St Vincent's Hospital, Sydney
Phase 1/2 Recruiting
NCT06119685 2025-06-03
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Phase 1/2 Recruiting
NCT05821686 2025-02-12
Efficacy of Interleukin-2 in Triple Negative Breast Cancer
Nova Scotia Health Authority
Phase 1/2 Not yet recruiting
NCT05207722 2024-12-12
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Celularity Incorporated
Phase 1/2 Terminated
NCT03318900 2024-11-07
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT01740557 2024-10-08
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03658785 2024-08-13
Immunotherapy for the Treatment of Advanced Solid Tumor
Tongji Hospital
Phase 1/2 Recruiting
NCT01898793 2024-01-17
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
Phase 1/2 Terminated
NCT06152367 2023-11-30
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
University of Chile
Phase 1/2 Completed
NCT01823198 2023-11-07
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT02414945 2023-01-10
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
University Health Network, Toronto
Phase 1/2 Completed
NCT00945269 2022-11-15
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01640301 2022-07-14
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00924326 2022-01-12
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02770820 2021-10-29
Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02408016 2021-09-13
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT04389229 2020-12-16
OVSTAR
Immetacyte Ltd
Phase 1/2 Withdrawn
NCT03778619 2020-07-28
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
GC Cell Corporation
Phase 1/2 Unknown
NCT01701479 2020-07-14
LTI
St. Anna Kinderkrebsforschung
Phase 1/2 Unknown
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT02390739 2019-12-16
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT01218867 2019-12-10
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01454596 2019-08-21
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02173093 2019-01-29
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
University of Virginia
Phase 1/2 Unknown
NCT00303667 2017-12-28
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 1/2 Completed
NCT00625729 2017-12-28
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1/2 Terminated
NCT03040401 2017-12-19
A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
Vastra Gotaland Region
Phase 1/2 Unknown
NCT02280811 2017-09-06
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00062036 2017-07-02
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00871481 2017-04-19
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01758458 2017-04-19
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated